Baolingbao Biology Co.,Ltd.

blb-cn.com

BAOLINGBAO BIOLOGY CO.,LTD is a leading Chinese producer of starch-based health and food ingredients. The company mainly provide erythritol, isomaltitol L-glutamine, isomaltooligosaccharide-900/500, malto-oligosacchardie, xylo-oligosaccharide, fructo-oligosaccharide, indigestible dextrin, polydextrose, beta-cyclodextrin, high fructose corn syrup, dextrose monohydrate, liquid glucose,Corn gluten meal and so on.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industry Outlook

CABALETTA BIO AND WUXI ADVANCED THERAPIES ANNOUNCE EXPANSION OF GMP MANUFACTURING AGREEMENT TO INCLUDE CABA-201

Globenewswire | August 23, 2023

news image

Cabaletta Bio, Inc. a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that it has entered into certain work orders relating to Good Manufacturing Practice (GMP) manufacturing under its existing master services agreement with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO). As part of the agreement, WuXi ...

Read More

AI

VIVA BIOTECH AND BIOMAP HAVE SIGNED A STRATEGIC COLLABORATION AGREEMENT TO ACCELERATE EARLY DRUG DISCOVERY USING AI TECHNOLOGY

Viva Biotech, BioMap | May 11, 2021

news image

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...

Read More

Medical

GATOR BIO SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH I&L BIOSYSTEMS

Gator Bio, Inc. | June 02, 2022

news image

Gator Bio, the next gen Biolayer Interferometry solutions company, has signed an agreement with I&L Biosystems GmbH, a distributor of innovative biomedical technology and products. The agreement will allow Gator Bio to expand rapidly its product offerings into the European Union, a key region for Gator's growth strategy as it begins its global reach. I&L Biosystems has a history of bringing new and innovative technologies into market — as ev...

Read More

Cell and Gene Therapy

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris | October 06, 2021

news image

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More
news image

Industry Outlook

CABALETTA BIO AND WUXI ADVANCED THERAPIES ANNOUNCE EXPANSION OF GMP MANUFACTURING AGREEMENT TO INCLUDE CABA-201

Globenewswire | August 23, 2023

Cabaletta Bio, Inc. a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that it has entered into certain work orders relating to Good Manufacturing Practice (GMP) manufacturing under its existing master services agreement with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO). As part of the agreement, WuXi ...

Read More
news image

AI

VIVA BIOTECH AND BIOMAP HAVE SIGNED A STRATEGIC COLLABORATION AGREEMENT TO ACCELERATE EARLY DRUG DISCOVERY USING AI TECHNOLOGY

Viva Biotech, BioMap | May 11, 2021

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...

Read More
news image

Medical

GATOR BIO SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH I&L BIOSYSTEMS

Gator Bio, Inc. | June 02, 2022

Gator Bio, the next gen Biolayer Interferometry solutions company, has signed an agreement with I&L Biosystems GmbH, a distributor of innovative biomedical technology and products. The agreement will allow Gator Bio to expand rapidly its product offerings into the European Union, a key region for Gator's growth strategy as it begins its global reach. I&L Biosystems has a history of bringing new and innovative technologies into market — as ev...

Read More
news image

Cell and Gene Therapy

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris | October 06, 2021

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More